Lysoway advances novel drug LW-1017 for Parkinson’s and Alzheimer’s
Lysoway Therapeutics announced the publication of preclinical data on LW-1017 in Scientific Reports. According to the company, LW-1017 is a novel, potent and highly brain-penetrant small-molecule agonist of TRPML1 that activated the channel with nanomolar potency and induced nuclear translocation of
<p>Lysoway Therapeutics announced the publication of preclinical data on LW-1017 in Scientific Reports. According to the company, LW-1017 is a novel, potent and highly brain-penetrant small-molecule agonist of TRPML1 that activated the channel with nanomolar potency and induced nuclear translocation of</p>